推进AAV载体制造:基因治疗的挑战,创新和未来方向
N Charan S S Kowshik1, Pushpendra Singh2
1Ocugen India, Hyderabad, Telangana, India.
Frontiers in molecular medicine
|December 19, 2025
概括
制造基因治疗的腺相关病毒 (AAV) 载体需要克服产量和可扩展性的挑战. 在上游和下游加工方面的创新,以及设计质量,是稳健和可访问的AAV制造的关键.
科学领域:
- 生物技术和基因治疗制造业 制造业
背景情况:
- 腺相关病毒 (AAV) 载体对于基因疗法至关重要,但面临着制造障碍,如可变性,低产量和可扩展性问题.
- 目前的制造工艺需要优化,以满足对基于AAV的疗法的日益增长的需求.
研究的目的:
- 为强大的腺相关病毒 (AAV) 基因疗法制造提供全面的框架.
- 评估行业挑战和AAV生产中的最新技术创新.
主要方法:
- 对端到端AAV制造工艺的审查,包括上游 (细胞培养,转染) 和下游 (净化,填充-完成) 操作.
- 分析关键创新,如高密度 perfusion 培养物,先进的等离子体系统,下一代转染试剂和改进的色谱技术.
- 重点是通过设计质量 (QbD) 框架,过程特征,缩放模型和实验设计 (DoE).
主要成果:
- 上游创新提高了流程质量和病毒载体的生产力.
- 下游的进步改善了完全和空的AAV囊的分离.
- 通过严格的过程表征和DoE支持的质量设计框架对于强大的控制策略,过程验证和监管合规性至关重要.
结论:
- 实施先进技术和质量设计方法对于克服AAV制造挑战至关重要.
- 人工智能和连续制造的整合将加速开发更安全,更有效和个性化的AAV基因疗法.
更多相关视频
09:20Isolation of Next-Generation Gene Therapy Vectors through Engineering, Barcoding, and Screening of Adeno-Associated Virus AAV Capsid Variants
Published on: October 18, 2022
5.1K
07:43Author Spotlight: Addressing Regulatory Gaps in Molecular Studies by Quantifying Viral Vectors in Complex Matrices
Published on: July 14, 2023
2.8K
相关概念视频
Microorganisms in Medicine and Therapeutics
914
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
914
Gene Therapy
27.3K
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...
27.3K
